Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDROMEDA: 225Ac-PSMA-617 vs 177Lu-PSMA-617 + SBRT for Oligorecurrent Prostate Cancer
NCT07150715Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2025
- Primary completion
- Oct 2030
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of actinium-225 PSMA-617 in prostate adenocarcinoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Dec 2025; status: recruiting.
02
Drugs
actinium-225 PSMA-617
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT07150715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150715.